General form of registration statement for all companies including face-amount certificate companies

Note 3 - Fair Value Measurements 2

v3.24.4
Note 3 - Fair Value Measurements 2
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Notes to Financial Statements    
Fair Value Disclosures [Text Block]

3. Fair Value Measurements

 

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):

 

   

September 30, 2024

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Current assets:

                               

Money market funds

  $ 13,889     $     $     $ 13,889  

Total assets measured at fair value

  $ 13,889     $     $     $ 13,889  
                                 

Liabilities:

                               

Derivative liabilities - royalty agreement

  $     $     $ 1,418     $ 1,418  

Convertible notes payable

                13,250       13,250  

Total liabilities measured at fair value

  $     $     $ 14,668     $ 14,668  

 

   

December 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Current assets:

                               

Money market funds

  $ 7,203     $     $     $ 7,203  

Total assets measured at fair value

  $ 7,203     $     $     $ 7,203  
                                 

Liabilities:

                               

Derivative liabilities - royalty agreement

  $     $     $ 1,014     $ 1,014  

Total liabilities measured at fair value

  $     $     $ 1,014     $ 1,014  

 

Money market funds are highly liquid investments and are actively traded. The pricing information on the Company’s money market funds is based on quoted prices in active markets for identical securities. This approach results in a classification of these securities as Level 1 of the fair value hierarchy. Money market funds are cash equivalents and are included in cash and cash equivalents on the Company’s balance sheet as of September 30, 2024 and December 31, 2023.

 

The Company measures the Convertible Notes and warrant liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. These valuations use assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the Convertible Notes and warrant liabilities related to updated assumptions and estimates are recognized within the statements of operations. There were no changes in instrument-specific credit risk for the Notes for the periods ended September 30, 2024.

 

The fair value of the Convertible Notes and warrant liabilities may change significantly as additional data is obtained, impacting the Company’s assumptions regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods.

 

The key assumptions used to determine the fair value of the derivative liabilities – royalty agreement at September 30, 2024 and December 31, 2023 are as follows:

 

   

September 30, 2024

   

December 31, 2023

 

Discount rate

    24.0 %     25.0 %

Probability rate of achieving FDA approval of a product

    56.6 %     50.0 %

Expected term to FDA regulatory approval of a product (in years)

 

2.67

      3.50  

 

The following assumptions were used in determining the fair value of the Convertible Notes as of September 30, 2024:

 

   

September 30, 2024

 

Risk-free interest rate

    4.40 %

Volatility

    77.50 %

Dividend yield

    0.00 %

Probability-weighted remaining term (years)

    0.5  

Stock price

  $ 3.67  

 

The following tables provide reconciliations of the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at September 30, 2024 (in thousands):

 

Derivative Liabilities Royalty Agreement

 

   

Three Months

Ended September

30, 2024

   

Nine Months

Ended September

30, 2024

 

Balance, beginning of period

  $ 1,343     $ 1,014  

Fair value adjustments

    75       404  

Balance, end of the period

  $ 1,418     $ 1,418  

 

Convertible Notes Payable

 

   

Three Months

Ended September

30, 2024

   

Nine Months

Ended September

30, 2024

 

Balance, beginning of period

  $ 10,029     $ -  

Initial fair value at issuance

    -       10,000  

Issuance of convertible notes during the period

    2,433       2,433  

Accrued interest expense

    220       249  

Fair value adjustments

    568       568  

Balance, end of the period

  $ 13,250     $ 13,250  

 

3. Fair Value Measurements

 

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):

 

   

December 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Current assets:

                               

Money market funds

  $ 7,203     $     $     $ 7,203  

Total assets measured at fair value

  $ 7,203     $     $     $ 7,203  
                                 

Liabilities:

                               

Derivative liabilities – royalty agreement

  $     $     $ 1,014     $ 1,014  

Total liabilities measured at fair value

  $     $     $ 1,014     $ 1,014  

 

 

   

December 31, 2022

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Current assets:

                               

Money market funds

  $ 15,203     $     $     $ 15,203  

Total assets measured at fair value

  $ 15,203     $     $     $ 15,203  
                                 

Liabilities:

                               

Derivative liabilities – royalty agreement

  $     $     $ 1,499     $ 1,499  

Total liabilities measured at fair value

  $     $     $ 1,499     $ 1,499  

 

 

Money market funds are highly liquid investments and are actively traded. The pricing information on the Company’s money market funds is based on quoted prices in active markets for identical securities. This approach results in a classification of these securities as Level 1 of the fair value hierarchy. Money market funds are cash equivalents and are included in cash and cash equivalents on the Company’s balance sheet as of December 31, 2023 and 2022.

 

The key assumptions used to determine the fair value of the derivative liabilities – royalty agreement at December 31, 2023 and 2022 are as follows:

 

   

December 31,

 
   

2023

   

2022

 

Discount rate

    25.0 %     25.0 %

Probability rate of achieving FDA approval of a product

    50 %     50 %

Expected term to FDA regulatory approval of a product (in years)

    3.50       1.75  

 

The following table provides a reconciliation of the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

 

   

2023

   

2022

 

Derivative liabilities – royalty agreement

               

Balance at January 1

  $ 1,499     $ 1,199  

Fair value adjustments on derivative liabilities

    (485 )     300  

Balance at December 31

  $ 1,014     $ 1,499  

 

The derivative liabilities – royalty agreement is classified as long term on the Company’s balance sheets according to the estimated timing of the occurrence of the potential payments.

 

As discussed in Note 4 below, the Amended Ligand Agreement was initially measured at its estimated fair value. This nonrecurring fair value measurement was based upon Level 3 inputs. The Company estimated the fair value of the royalty agreement liability on the amendment date using a Monte Carlo valuation model. The Company derived risk-adjusted quarterly net sales forecasts by applying a net sales discount rate of 21% to its forecasted net sales over the royalty term, and then simulated the risk-adjusted net sales using a Monte Carlo simulation. Based on the simulated net sales, the Company estimated the royalty payments within each simulation path based on the contractual royalty rates, and then present valued the royalty payments using a discount rate of 22%, which was based on its estimated discrete weighted average cost of capital of 24.5% as of the amendment date, adjusted to reflect the continuously compounded nature of the analysis. The Company then averaged across all simulation paths to derive the fair value of the royalty agreement liability on the date of amendment of $7.8 million.